ICN adds to diagnostics business:
This article was originally published in Clinica
Executive Summary
ICN Pharmaceuticals is to acquire 40% of SeaLite Sciences, a private developer of hormonal diagnostic tests. Under the agreement, for which financial terms were not disclosed, ICN will produce and distribute SeaLite's products, including the AquaLite TSH test to detect thyroid disorders. US clearance was recently received for AquaLite and three other fertility kits. ICN will also distribute SeaLite's line of six research products. ICN, which will obtain two seats on SeaLite's board, will have the option to acquire the remaining 60% of the diagnostics company.